CDC funding bioterror research nationwide

Clinical surveillance, specific agents targeted

The Centers for Disease Control and Prevention (CDC) has awarded approximately $9 million in new grants to enhance biodefense and emerging infectious diseases research in the United States. The grants include:

National Animal Syndromic Surveillance for Bioterrorism, Lawrence T. Glickman, DVM, VMD, DrPH, Purdue University School of Veterinary Medicine, West Lafayette, IN. The project will use a nationwide animal health database and commercially available software to provide surveillance of syndromes to alert public health officials to natural or man-made environmental hazards.

Nanophotonics for Select Agent Detection, Ashutosh Chilkoti, PhD, Duke University, Durham, NC. The study will develop a sensor that measures biomolecular interactions in real time for detection of Category A bioterrorism pathogens.

Regulation of the Innate Immune Response to Bacillus Anthracis, Gary Bokoch, PhD, Scripps Research Institute, La Jolla, CA. This project will investigate in molecular detail how anthrax toxins interact with human host defense mechanisms.

CD8T Cell Response to Vaccinia Following Lymphopenia, Stephen C. Jameson, PhD, University of Minnesota Medical School, Minneapolis. This proposal studies the nature of antiviral T cell responses against the pox virus vaccinia and will further understanding of vaccination efficacy in immunodeficient individuals.

Response to Viral Infection in Immunodeficient Mice, Leslie J. Berg, PhD, University of Massachusetts Medical School, Worchester. This investigation will study T cell signaling pathways to better understand protective immunity to viral infection, including vaccinia virus.

Developing a Bioterrorism Syndromic Surveillance System, Trish M. Perl, MD, Johns Hopkins University Department of Medicine, Baltimore. This project will develop and validate a computerized patient record system-based prediction rule using electronically available laboratory data to track disease syndromes consistent with the characteristics of a bioterrorism event.

Discovery and Development of Biodefense Antimicrobials, Christopher J. Collins, PhD, SRI International, Menlo Park, CA. This investigation will develop new preclinical drug candidates for the treatment of infections caused by Category A bacteria, including anthrax.

Automated Simultaneous Detection of Bioterrorism Agents, David J. Ecker, PhD, IBIS Therapeutics, Carlsbad, CA. This study will complete the development, engineering, and validation of the infectious disease diagnostic platform that was created to detect a broad range of biological weapons agents in samples collected from the environment and will deploy a working version at CDC.